Faeth Therapeutics, Inc.
FTH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829802
No open-market purchases or sales by Faeth Therapeutics, Inc. insiders were filed in the last 90 days; 45 institutions reported holding it in 13F filings for Q2 2026, worth $333.8M in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Faeth Therapeutics, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 9 | 10 | +1 |
| Shares | 49.3K | 48.2K | −1.09K (−2.2%) |
| Value | $466.2K | $514.8K | +$48.6K (+10.4%) |
New holders (2)
Institutions that held Faeth Therapeutics, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citigroup Inc | 294 | $3.14K | 0.00% |
| BNP Paribas | 7 | $59 | 0.00% |
Sold out (1)
Institutions that held Faeth Therapeutics, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| UBS Group AG | 873 | $8.25K |